Considering that IL-8 signaling has been shown to be fundamentally involved in resistance of lung carcinoma cells to the EGFR TKI erlotinib [23], our results suggest that IL-8 action on response to EGFR TKIs may be dependent on cell context or types of TKIs-treatments. The gene discussed is CXCL8; the disease is lung carcinoma.